<DOC>
	<DOCNO>NCT02830620</DOCNO>
	<brief_summary>The syndrome anorexia-cachexie , accompany numerous cancer major comorbidity compromise forecast patient . Several cytokine pro-inflammatory interleukines IL1 ß , IL6 TNFa participate physiopathology syndrome man animal . Besides , establish different neuronal population , localize hypothalamus , nerve center control appetite energy homéostasie . However , enough evidence direct action cytokine neurones , suggest participation intermediate molecule chimiokines , inflammatory molecule produce reaction immunological stress gliales cell act directly surround neurones . The implication chimiokines syndrome anorexia-cachexie associate cancer thus seem likely Among , chimiokines `` Monocyte Chemoattractant Proteins 1-3 `` MCPs represent obvious candidate produce multiple tumor . Furthermore , mouse , intellectual expression MCP1 correlate anorexia lead peripheral injection bacterial by-product , lipopolysaccharide ( LPS ) . The investigator ' main objective test Man 's , situation cancer pancreas confuse stage , degree prédictivité chimiokine MCP1 towards syndrome anorexia-cachexie associated cancer . The investigator also suggest describe : ) link rate plasmatique MCP1 energy metabolism one hand , physical composition hand ; ; ii ) impact chimiokines , particularly family MCPs , anorexia-cachexie bound cancer , iii ) correlation enters profile expression plasmatique severity anorexia , energy metabolism physical composition ; iv ) research inflammatory factor plasmatiques , nature different chimiokines ; v ) correlation thin mass anorexia ; vi ) evolution chimiokines various inflammatory factor surgical treatment chemotherapy curative aim 6 month .</brief_summary>
	<brief_title>Study Man Profile Chimiokines Anorexia Bound Cancerous Cachexy</brief_title>
	<detailed_description />
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Group 1 { cancer pancreas WITH syndrome anorexiacachexie } Patient hospitalize unit digestive cancer research . Patient ≥ 18 year . Patient carrier adénocarcinome pancreas novo , stadium confuse , diagnose image and/or histology . Existence least one criterion follow hold ( retain ) diagnosis cachexie cancer patient : deliberate loss weight &gt; 5 % last 6 month OR ( WHERE ) IMC ( CEREBRALMOTOR HANDICAPPED ) &lt; 20 kg / ² loss minimum weight &gt; 2 % OR ( WHERE ) scrawny muscular index appendiculaire respectively &lt; 7,26 kg / ² man &lt; 5,45 kg / ² woman minimal weight loss &gt; 2 % . Patient sign enlightened consent . Patient tumor one pancreatic adénocarcinome . Patient second offense adénocarcinome pancreatic . Patient carrier pancreatic adénocarcinome course treatment chemotherapy . Patient severe psychiatric comorbidity except TCA responsible food disorder . Patient carrier evolutionary inflammatory disease one cancer able interfere inflammatory status . Groupe 2 { cancer du pancréas SANS syndrome d'anorexiecachexie } Patient hospitalize ( unit ) digestive cancer research . Patient ≥ 18 year . Patient carrier adénocarcinome pancreas novo , stadium confuse , diagnose image and/or histology . Patient sign enlightened consent . Patient tumor one pancreatic adénocarcinome . Patient second offense ( recurrence ) adénocarcinome pancreatic . Patient carrier pancreatic adénocarcinome course treatment chemotherapy . Existence least one criterion favour diagnosis cachexie cancer patient : deliberate loss weight &gt; 5 % last 6 month OR ( WHERE ) IMC ( CEREBRALMOTOR HANDICAPPED ) &lt; 20 kg / ² loss minimum weight &gt; 2 % OR ( WHERE ) scrawny muscular index appendiculaire respectively &lt; 7,26 kg / ² man &lt; 5,45 kg / ² woman minimal weight loss &gt; 2 % . Patient severe psychiatric comorbidity except TCA responsible food disorder . Patient carrier evolutionary inflammatory disease one cancer able interfere inflammatory status . Patient refuse participate study Under guardianship patient guardianship . Group 3 { pure food limitation typifies restrictive anorexia nervosa } Patient see consultation unit nutritional support ( medium ) Patient ≥ 18 year . Patient carrier eat disorder type pure restrictive anorexia nervosa ( accord criterion diagnosis WHO ) Patient sign enlightened consent . Patient evolutionary organic pathology source decrease oral contribution and/or interference inflammatory status , responsible loss weight Patient refuse participate study Under guardianship patient guardianship . Group 4 { unhurt individual appetitesuppressing evolutionary disease cachectisante } Patient see consultation hepatogastroenterology Patient ≥ 18 year . Unhurt patient organic psychic , evolutionary pathology , cachectisante Patient sign enlightened consent . Patient refuse participate study Under guardianship patient guardianship .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>